Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03350542 · ClinicalTrials.gov registry record · Phase 3
A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)
A Phase 3 study, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT03350542 is a Phase 3 study that has completed, run by Boston Scientific Corporation. The registered enrollment target is 100 participants.
The verdict
NCT03350542, a Phase 3 study, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
EVOLVE 48 is a prospective, open label, single arm, multi-center trial. The purpose of this study is to assess the FDA requirement for safety and effectiveness of the SYNERGY 48 mm Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) \> 34 mm and ≤ 44 mm in length (by visual estimate) in native coronary arteries ≥2.5 mm to ≤4.0 mm in diameter (by visual estimate).
Interventions
- DEVICE SYNERGY 48 mm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-04-12 |
| Est. Completion | 2021-01-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03350542
The ClinicalTrials.gov registry entry for NCT03350542 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SYNERGY 48 mm is the first listed.
NCT03350542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03350542 about?
NCT03350542 is a clinical study titled "A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)". EVOLVE 48 is a prospective, open label, single arm, multi-center trial. The purpose of this study is to assess the FDA requirement for safety and effectiveness of the SYNERGY 48 mm Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) \> 34 mm and ≤ 44 mm in length (by v...
What is the current status of trial NCT03350542?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2018-04-12. Estimated completion is 2021-01-08.
What interventions are being tested in trial NCT03350542?
The interventions under investigation include: SYNERGY 48 mm (DEVICE).
Who is sponsoring clinical trial NCT03350542?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.